Current Controversies in Viral Hepatitis

CCO HEP 2018 Annual Update Program Image

Led by Paul Martin, MD, a panel of experts discusses their management approach to several controversial clinical scenarios, including whether to treat patients with immune-tolerant HBV infection, whether all patients receiving suppressive TDF for the treatment of HBV infection should be switched to TAF, if it is reasonable to discontinue oral therapy in select patients with HBeAg-negative HBV infection who do not have cirrhosis, and whether increased engagement by liver disease specialists will be needed to reach HCV elimination goals by 2030.

Norah Terrault, MD, MPH
Program Director
Paul Martin, MD
Christian Ramers Headshot
Christian B. Ramers, MD, MPH
Nancy Reau, MD
Physicians: maximum of 1.25 AMA PRA Category 1 Credits
Registered Nurses: 1.2 Nursing contact hours
Pharmacists: 1.25 contact hours (0.125 CEUs)
Released: July 6, 2018 Expiration: July 5, 2019

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Select guideline-recommended, evidence-based management strategies for patients with different phases of chronic HBV infection
  • Apply key guidelines and study data to ensure appropriate, individualized management for diverse patient populations with chronic HBV infection, based on individual patient factors
  • Implement practical strategies to optimize outcomes in patients receiving therapy for chronic HBV infection

Information on this Educational Activity

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Program Director

Norah Terrault, MD, MPH

Professor of Medicine and Surgery
Director, Viral Hepatitis Center
Division of Gastroenterology
University of California, San Francisco
San Francisco, California

Norah Terrault, MD, MPH, has disclosed that she has received consulting fees from ADMA Biologics, Dova, and Merck and funding for research support from AbbVie, ADMA Biologics, Allergan, Bristol-Myers Squibb, Eisai, Gilead Sciences, Grifols, Lion TCR, Merck, and Perspectum Diagnostics.

Faculty

Paul Martin, MD

Chief
Division of Gastroenterology and Hepatology
University of Miami School of Medicine
Miami, Florida

Paul Martin, MD, has disclosed that he has received consulting fees from AbbVie and Merck and funds for research support from AbbVie, Gilead Sciences, and Merck.
Christian B. Ramers, MD, MPH

Associate Clinical Professor
Division of Infectious Diseases
Department of Medicine
UC San Diego School of Medicine
La Jolla, California
Chief, Population Health
Director, Graduate Medical Education
Family Health Centers of San Diego
San Diego, California

Christian B. Ramers, MD, MPH, has disclosed that he has received consulting fees from AbbVie, Bristol-Myers Squibb, and Gilead Sciences; fees for non-CME/CE services received directly from a commercial interest or their agents (eg, speaker bureaus) from AbbVie, Gilead Sciences, Janssen, and Merck; and funds for research support from Gilead Sciences.
Nancy Reau, MD

Professor of Medicine
Chief,
Section of Hepatology
Associate Director, Solid Organ Transplantation
Richard B. Capps Chair of Hepatology
Rush University Medical Center
Chicago, Illinois

Nancy Reau, MD, FAASLD, AGAF, has disclosed that she has received consulting fees from AbbVie, Gilead Sciences, and Merck and funds for research support from AbbVie.

Staff

Jenny Schulz, PhD

Director, Scientific Services

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.
Jennifer Blanchette, PhD

Senior Scientific Director

Jennifer M. Blanchette, PhD, has no real or apparent conflicts of interest to report.
Megan K. Murphy, PhD

Scientific Director

Megan K. Murphy, PhD, has no real or apparent conflicts of interest to report.

The PIM planners and managers have nothing to disclose.

Charles E. Willis, Director of Continuing Education from the Annenberg Center for Health Sciences at Eisenhower consults for Pfizer, Inc.; Amanda Sewell, MBA, Manager of Continuing Education and Melissa Velasquez, Accreditation Specialist both from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for infectious diseases clinicians, hepatologists, gastroenterologists, registered nurses, pharmacists, and other healthcare professionals involved in the care of patients with viral hepatitis.

Goal

The goal of this activity is to improve participants’ competence in addressing the most important and most current challenges in viral hepatitis management by providing a tightly focused update on recent advances and key clinical issues encountered in the clinic.

Physician Continuing Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Accreditation Statement

Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Credit Designation

1.2 contact hour may be earned for successful completion of this activity.

Pharmacist Continuing Education

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

This program is assigned ACPE Universal Activity 0797-9999-18-086-H01-P. This program is designated for up to 1.25 contact hours (0.125 CEUs) of continuing pharmacy education credit.

Type of Activity Application

For Pharmacists: Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 06, 2018, through July 05, 2019:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Download free expert-authored slides reviewing HBV management recommendations for specific patient populations and learn how expert faculty approach complex cases

person default Joseph Ahn, MD, MS, MBA Anna Christina L. dela Cruz, MD Released: July 21, 2020

Watch this interactive presentation from CCO to learn how expert faculty weigh factors to determine the optimal management strategy for complex patients with HBV infection

Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
Program Director
person default Joseph Ahn, MD, MS, MBA Anna Christina L. dela Cruz, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: July 20, 2020 Expired: July 19, 2021

CCO commentary from Pietro Lampertico, MD, PhD, on the pros and cons of discontinuing NA therapy in patients with chronic HBV

person default Pietro Lampertico, MD, PhD Released: July 10, 2020

Watch this interactive presentation from CCO to learn how expert faculty weigh factors to determine treatment candidacy, individualize treatment, and effectively monitor patients with HBV infection

Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
Program Director
Steven L. Flamm, MD
Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: July 7, 2020 Expired: July 6, 2021
Jointly provided by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Educational grants provided by
AbbVie
Gilead Sciences
Janssen Therapeutics
Merck & Co., Inc.
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?